Interventional Cardiology Clinic, Department of Interventional Cardiology and Electrocardiology, Central Clinical Hospital, Pomorska 251, 92-213 Lodz, Poland.
Dis Markers. 2021 May 17;2021:8821292. doi: 10.1155/2021/8821292. eCollection 2021.
FGF23 is a hormone secreted mainly by osteocytes and osteoblasts in bone. Its pivotal role concerns the maintenance of mineral ion homeostasis. It has been confirmed that phosphate and vitamin D metabolisms are related to the effect of FGF23 and its excess or deficiency leads to various hereditary diseases. Multiple studies have shown that FGF23 level increases in the very early stages of chronic kidney disease (CKD), and its concentration may also be highly associated with cardiac complications. The present review is limited to some of the most important aspects of calcium and phosphate metabolism. It discusses the role of FGF23, which is considered an early and sensitive marker for CKD-related bone disease but also as a novel and potent cardiovascular risk factor. Furthermore, this review gives particular attention to the reliability of FGF23 measurement and various confounding factors that may impact on the clinical utility of FGF23. Finally, this review elaborates on the clinical usefulness of FGF23 and evaluates whether FGF23 may be considered a therapeutic target.
成纤维细胞生长因子 23（FGF23）是一种主要由骨细胞和成骨细胞分泌的激素。其关键作用涉及维持矿物质离子的体内平衡。已经证实，磷酸盐和维生素 D 的代谢与 FGF23 的作用有关，其过多或过少会导致各种遗传性疾病。多项研究表明，慢性肾脏病（CKD）的早期阶段 FGF23 水平升高，其浓度也可能与心脏并发症高度相关。本综述仅限于钙和磷酸盐代谢的一些最重要的方面。它讨论了 FGF23 的作用，FGF23 被认为是 CKD 相关骨骼疾病的早期和敏感标志物，但也是一种新的、强有力的心血管危险因素。此外，本综述特别关注 FGF23 测量的可靠性以及可能影响 FGF23 临床应用的各种混杂因素。最后，本综述阐述了 FGF23 的临床应用，并评估了 FGF23 是否可以被认为是一个治疗靶点。
